Zurich, Switzerland, June 22, 2009
Covagen (CH) and Roche (CH) announced today that they have entered a collaboration
agreement under which Covagen will use its protein engineering technology to isolate
Fynomers – a novel class of protein-based drugs - binding to undisclosed targets provided by
Roche. Fynomers delivered by Covagen will be further tested and evaluated by Roche to
discover potential new treatments for patients with unmet medical needs. The financial terms
of the collaboration agreement were not disclosed.
Dr. Julian Bertschinger, CEO and co-founder of Covagen commented: “We are proud to enter a collaboration with Roche, one of the leading science-based healthcare companies in the field of biopharmaceuticals.” Dr. Dragan Grabulovski, CSO and co-founder of Covagen added: “This collaboration with Roche represents a further step to establish Covagen’s Fynomers as new binding proteins for a variety of applications in drug discovery.”
